Invasive Breast Cancer
81
12
24
31
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
16 trials with published results (20%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
7.4%
6 terminated out of 81 trials
83.8%
-2.8% vs benchmark
9%
7 trials in Phase 3/4
52%
16 of 31 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 31 completed trials
Clinical Trials (81)
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
Proton Radiation Therapy for Invasive Breast Cancer Following Mastectomy
Sacituzumab Govitecan In TNBC
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Observational Study of Intra-operative Partial Irradiation of Invasive Ductal Breast Carcinomas With a Good Prognosis
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
Genetic Testing for All Breast Cancer Patients (GET FACTS)
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Patient-Derived Breast Cancer Organoids for Therapeutic Extracellular Vesicle Isolation (PDO-Mercurial01)
Onvansertib + Paclitaxel In TNBC
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases
Olaparib In Metastatic Breast Cancer
FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer